The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Items 201–300 of 1,002
Li, Y.-R., Li, Z., Zhu, Y., Li, M., Chen, Y., Lee, D. P. H., Ochoa, C. J., Singh, T., DiBernardo, G., Guo, W., et al. (2025) · Med · doi:10.1016/j.medj.2025.100804 · Cited by 62
TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies
Cui, H., Hamad, M. A., & Elkord, E. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07984-4 · Cited by 59
Wei, J., Montalvo-Ortiz, W., Yu, L., Krasco, A., Olson, K., Rizvi, S., Fiaschi, N., Coetzee, S., Wang, F., Ullman, E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1082 · Cited by 54
CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer
Włodarczyk, M., & Pyrzyńska, B. (2022) · Cancers · doi:10.3390/cancers15010117 · Cited by 54
Bispecific Antibodies in Hematological Malignancies: A Scoping Review
Omer, M. H., Shafqat, A., Ahmad, O., AlKattan, K. M., Yaqinuddin, A., & Damlaj, M. (2023) · Cancers · doi:10.3390/cancers15184550 · Cited by 60
CAR-T cell therapy for hematological malignancies: History, status and promise
Wang, C., Wang, J., Che, S., & Hai, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21776 · Cited by 64
Calabrò, A., Accardi, G., Aiello, A., Caruso, C., Galimberti, D., & Candore, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031792 · Cited by 57
Molecular glues and induced proximity: An evolution of tools and discovery
Robinson, S. A., Co, J., & Banik, S. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.04.001 · Cited by 58
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 58
Nano-formulations in disease therapy: designs, advances, challenges, and future directions
Shi, Y., Li, X., Li, Z., Sun, J., Gao, T., Wei, G., & Guo, Q. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03442-7 · Cited by 58
Surface engineering of nanoparticles for precision medicine
Zheng, J., Sun, Y., Shen, Y., & Zhou, Z. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100037 · Cited by 55
Gavali, S., Liu, J., Li, X., & Paolino, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910800 · Cited by 53
T Lymphocyte and CAR-T Cell-Derived Extracellular Vesicles and Their Applications in Cancer Therapy
Calvo, V., & Izquierdo, M. (2022) · Cells · doi:10.3390/cells11050790 · Cited by 56
Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., Xing, C., Chen, Q., Du, Y., Duan, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004035 · Cited by 53
Genetically engineered cellular nanoparticles for biomedical applications
Krishnan, N., Peng, F.-X., Mohapatra, A., Fang, R. H., & Zhang, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122065 · Cited by 56
Biomaterial‐based gene therapy
Yu, Y., Gao, Y., He, L., Fang, B., Ge, W., Pu, Y., Ju, Y., Xie, X., & Lei, L. (2023) · MedComm · doi:10.1002/mco2.259 · Cited by 55
Stein, M. N., Dumbrava, E. E. I., Teply, B. A., Gergis, U. S., Guiterrez, M., Reshef, R., Subudhi, S. K., Jacquemont, C. F., Senesac, J. H., Bayle, J. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53220-6 · Cited by 53
Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology
Youssef, E. M., Fletcher, B., & Palmer, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1527600 · Cited by 63
Engineering nanosystems to overcome barriers to cancer diagnosis and treatment
Alhaj-Suliman, S. O., Wafa, E. I., & Salem, A. K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114482 · Cited by 53
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Sun, F., Cheng, Y., Wanchai, V., Guo, W., Mery, D. E., Xu, H., Gai, D., Siegel, E. R., Bailey, C., Ashby, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44873-4 · Cited by 55
The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies
Hu, M., Deng, F., Song, X., Zhao, H., & Yan, F. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03115-7 · Cited by 57
Next-generation cancer vaccines and emerging immunotherapy combinations
Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 52
SynNotch CAR-T cell, when synthetic biology and immunology meet again
Shirzadian, M., Moori, S., Rabbani, R., & Rahbarizadeh, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545270 · Cited by 55
Azeez, S. S., Yashooa, R. K., Smail, S., Salihi, A., Ali, A. S., Mamand, S., & Janson, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02386-8 · Cited by 56
CAR T cell therapies for diffuse midline glioma
Thomas, B. C., Staudt, D. E., Douglas, A. M., Monje, M., Vitanza, N. A., & Dun, M. D. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.007 · Cited by 53
Wang, C., Sun, X., Feng, L., & Liu, Z. (2024) · BMEMat · doi:10.1002/bmm2.12083 · Cited by 52
CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges
Zhou, Y., Wei, S., Xu, M., Wu, X., Dou, W., Li, H., Zhang, Z., & Zhang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489649 · Cited by 51
Progress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
Kamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01430-8 · Cited by 50
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
Dezfouli, A. B., Yazdi, M., Pockley, A. G., Khosravi, M., Kobold, S., Wagner, E., & Multhoff, G. (2021) · Cells · doi:10.3390/cells10123390 · Cited by 53
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 54
Gene Therapy Strategies Targeting Aging-Related Diseases
Yu, J., Li, T., & Zhu, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.00725 · Cited by 53
Engineering considerations of iPSC-based personalized medicine
Park, S., Gwon, Y., Khan, S. A., Jang, K., & Kim, J. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00382-x · Cited by 52
Huang, M., Ji, Q., Huang, H., Wang, X., & Wang, L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2486519 · Cited by 53
Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 59
Mercanti, L., Sindaco, M., Mazzone, M., Marcantonio, M. C. D., Piscione, M., Muraro, R., & Mincione, G. (2023) · Cancers · doi:10.3390/cancers15112923 · Cited by 55
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Dang, B.-T. N., Kwon, T. K., Lee, S., Jeong, J., & Yook, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.007 · Cited by 51
The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy
Boretti, A. A. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109137 · Cited by 53
Jing, W., Han, M., Wang, G., Kong, Z., Zhao, X., Fu, Z., Jiang, X., Shi, C., Chen, C., Zheng, Z., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00950-1 · Cited by 58
Lee, D., Dunn, Z. S., Guo, W., Rosenthal, C. J., Penn, N. E., Yu, Y., Zhou, K., Li, Z., Ma, F., Li, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42619-2 · Cited by 49
Metabolic engineering for optimized CAR-T cell therapy
McPhedran, S. J., Carleton, G. A., & Lum, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00976-2 · Cited by 51
CAR-macrophage: Breaking new ground in cellular immunotherapy
Huang, T., Bei, C., Hu, Z., & Li, Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1464218 · Cited by 52
Tumor-Associated Extracellular Matrix Obstacles for CAR-T Cell Therapy: Approaches to Overcoming
Klabukov, I., Kabakov, A. E., Yakimova, A. O., Baranovskii, D., Сосин, Д. В., Atiakshin, D., Ignatyuk, M. A., Yatsenko, E., Rybachuk, V. A., Evstratova, E. S., et al. (2025) · Current Oncology · doi:10.3390/curroncol32020079 · Cited by 52
Antibody‐Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds
Adhikari, A., & Chen, I. A. (2025) · Small · doi:10.1002/smll.202409635 · Cited by 53
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Simão, D. C., Zarrabi, K. K., Mendes, J. L., da Luz, R., Garcia, J. A., Kelly, W. K., & Barata, P. C. (2023) · Cancers · doi:10.3390/cancers15051412 · Cited by 47
Dong, Z., Liu, Y., Wang, C., Hao, Y., Fan, Q., Yang, Z., Li, Q., Feng, L., & Liu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202308254 · Cited by 47
Mechanisms and management of CAR T toxicity
Ferreri, C. J., & Bhutani, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1396490 · Cited by 56
Challenges and innovations in CAR-T cell therapy: a comprehensive analysis
Luo, J., & Zhang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1399544 · Cited by 48
Synthetic Biology‐Based Engineering Cells for Drug Delivery
Yi, W., Hu, S., Qian, X., Yan, W., & Li, Y. (2025) · Exploration · doi:10.1002/exp.20240095 · Cited by 49
Nano-drug delivery systems for T cell-based immunotherapy
Li, R. P., Chen, Z., Li, J., Dai, Z., & Yu, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101621 · Cited by 48
Cancer Immunotherapy and Delivery System: An Update
Yang, M. J., Olaoba, O. T., Zhang, C., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081630 · Cited by 46
Cancer immunotherapy strategies that target the cGAS-STING pathway
Tian, Z., Zeng, Y., Peng, Y., Liu, J., & Wu, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996663 · Cited by 47
Immune surveillance of senescence: potential application to age-related diseases
Wang, T., & Nakanishi, M. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.06.007 · Cited by 49
Huang, S., Chung, J. Y., Li, C., Wu, Y., Qiao, G., To, K., & Tang, P. M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217272 · Cited by 49
Baharom, F., Hermans, D., Delamarre, L., & Seder, R. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01091-9 · Cited by 47
Frisch, A. T., Wang, Y., Xie, B., Yang, A., Ford, B. R., Joshi, S. K., Kedziora, K. M., Peralta, R. M., Wilfahrt, D. N., Mullett, S. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.12.007 · Cited by 50
Erasha, A. M., El-Gendy, H. F., Aly, A. S., Fernández‐Ortiz, M., & Sayed, R. K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062716 · Cited by 52
Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy
Hou, Y., Hu, S., Chong, L., Chen, X., Wang, Y., Li, Y., Fu, Z., Feng, C., Gong, Y., Liu, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1675807 · Cited by 52
Glioblastoma microenvironment—from biology to therapyPreprint
Read, R. D., Tapp, Z. M., Rajappa, P., & Hambardzumyan, D. (2024) · Genes & Development · doi:10.1101/gad.351427.123 · Cited by 51
Ahmad, U., Khan, Z., Ualiyeva, D., Amissah, O. B., Noor, Z., Khan, A., Zaman, N., Khan, M., Khan, A., & Ali, B. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100035 · Cited by 45
Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Zhao, Y. F., Bai, Y., Shen, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992762 · Cited by 46
Current status of immunotherapy for non-small cell lung cancer
Yang, T., Xiong, Y., Zeng, Y., Wang, Y., Zeng, J., Liu, J., Xu, S., & Li, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989461 · Cited by 45
Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches
Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 45
Zhong, L., Li, Y., Muluh, T. A., & Wang, Y. (2023) · Oncology Letters · doi:10.3892/ol.2023.13867 · Cited by 47
Bressler, E. M., Adams, S. C., Liu, R., Colson, Y. L., Wong, W. W., & Grinstaff, M. W. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1244 · Cited by 45
Li, Y., Shen, L., Jiang, Z., Tan, K., Meng, Y., Zhang, D., & Ma, X. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01977-1 · Cited by 48
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
Ser, M. H., Webb, M., Sener, U. T., & Campian, J. L. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-34 · Cited by 51
Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence
Czaplicka, A., Lachota, M., Pączek, L., Zagożdżon, R., & Kaleta, B. (2024) · Cells · doi:10.3390/cells13010101 · Cited by 47
Ouladan, S., & Orouji, E. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02081 · Cited by 48
Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 55
Technological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 59
How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy
Biederstädt, A., & Rezvani, K. (2022) · Blood · doi:10.1182/blood.2021012411 · Cited by 45
Next Generation Natural Killer Cells for Cancer Immunotherapy
Rossi, F., Fredericks, N., Snowden, A., Allegrezza, M. J., & Moreno‐Nieves, U. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886429 · Cited by 47
Keshavarz, A., Salehi, A., Khosravi, S., Shariati, Y., Nasrabadi, N., Kahrizi, M. S., Maghsoodi, S., Mardi, A., Azizi, R., Jamali, S., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03163-w · Cited by 47
Bright future or blind alley? CAR-T cell therapy for solid tumors
Zhang, K., Chen, H., Li, F., Sheng, H., Chen, F., & Li, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1045024 · Cited by 48
The Interplay between Integrins and Immune Cells as a Regulator in Cancer Immunology
Zhang, Q., Zhang, S., Chen, J., & Xie, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076170 · Cited by 44
CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
Chen, K., Liu, M., Wang, J., & Fang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9675 · Cited by 49
Wang, B., Zhou, J., Li, R., Tang, D., Cao, Z., Xu, C., & Xiao, H. (2024) · Advanced Materials · doi:10.1002/adma.202311640 · Cited by 44
S, K. D. S., Joga, R., Srivastava, S., Nagpal, K., Dhamija, I., Grover, P., & Kumar, S. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114361 · Cited by 44
Entezam, M., Sanaei, M., Mirzaei, Y., Mer, A. H., Abdollahpour‐Alitappeh, M., Azadegan‐Dehkordi, F., & Bagheri, N. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121459 · Cited by 44
CRISPR-Cas System: The Current and Emerging Translational Landscape
Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 46
Zhu, W., Zhang, Z., Chen, J., Chen, X., Huang, L., Zhang, X., Huang, X., Ma, N., Xu, W., Yi, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01792-6 · Cited by 43
T cell-based cancer immunotherapy: opportunities and challenges
Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.03.054 · Cited by 47
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Liu, N., Wang, X., Wang, Z., Yonemori, K., Fang, Y., Gao, J., Kong, X., & Wang, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01692-4 · Cited by 49
Immunomodulatory role of metalloproteases in cancers: Current progress and future trends
Wang, Q., Wang, K., Tan, X., Li, Z., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1064033 · Cited by 42
CAR T cells: engineered immune cells to treat brain cancers and beyond
Huang, Z., Dewanjee, S., Chakraborty, P., Jha, N. K., Dey, A., Gangopadhyay, M., Chen, X.-Y., Wang, J., & Jha, S. K. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01712-8 · Cited by 46
Immunotherapies in rare cancers
Vivekanandhan, S., Bahr, D. A., Kothari, A., Ashary, M. A., Baksh, M., & Gabriel, E. M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01720-2 · Cited by 43
Akhoundova, D., Seipel, K., Bacher, U., Kronig, M.-N., Porret, N. A., Wiedemann, G., Daskalakis, M., & Pabst, T. (2023) · BMC Cancer · doi:10.1186/s12885-023-10824-3 · Cited by 44
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Chen, Z., Hu, Y., & Mei, H. (2023) · Advanced Science · doi:10.1002/advs.202303215 · Cited by 46
CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy
Ding, S., Liu, J., Han, X., & Tang, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216325 · Cited by 51
Lu, S., Zhang, C., Wang, J., Zhao, L., & Li, G. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116059 · Cited by 44
Chen, H., Bao, Y., Li, X., Chen, F., Sugimura, R., Zeng, X., & Xia, J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410566 · Cited by 42
Sun, L., Liu, Y., Sun, Q., Wang, G., Du, B., Liu, B., Gao, T., Zhao, P., Yang, Y., & Rong, R. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.123416 · Cited by 42
Early methionine availability attenuates T cell exhaustion
Sharma, P., Guo, A., Poudel, S., Boada-Romero, E., Verbist, K., Palacios, G., Immadisetty, K., Chen, J., Haydar, D., Mishra, A., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02223-6 · Cited by 45
Engineered Treg cells: The heir to the throne of immunotherapy
Stucchi, A., Maspes, F., Montee-Rodrigues, E., & Fousteri, G. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102986 · Cited by 43
Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy
Li, W., Jiang, Y., & Lu, J. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122655 · Cited by 42
CircRNAs in tumor immunity and immunotherapy: Perspectives from innate and adaptive immunity
Yu, L., Xiao, Q., Yu, B., Lv, Q., Liu, Z., & Yin, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216219 · Cited by 41
Mun, S. S., Meyerberg, J., Peraro, L., Korontsvit, T., Gardner, T. J., Malviya, M., Kyi, C., O'Cearbhaill, R. E., Liu, C., Dao, T., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03529-w · Cited by 42
Paun, R. A., Jurchuk, S., & Tabrizian, M. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10601 · Cited by 48
Palacios, A. M., Korus, P., Wilkens, B. G. C., Heshmatpour, N., & Patnaik, S. R. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1342193 · Cited by 49
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
